Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on November 24 backed approval for MSD’s immune checkpoint inhibitor Keytruda (pembrolizumab) for the treatment of PD-L1-positive unresectable, advanced or relapsed non-small cell lung cancer (NSCLC) both...read more